The development of a goiter and hypothyroidism in a 28-year-old man in whom metastatic melanoma had been treated with interleukin-2 and lymphokine-activated killer cells (LAK cells) prompted us to assess thyroid function in patients undergoing this therapy. Thirty-four patients with advanced neoplasms who had received interleukin-2 and LAK cells were followed for at least four weeks after treatment. Seven patients (21 percent) had laboratory evidence of hypothyroidism, with a decline in the serum thyroxine concentration to below normal (less than or equal to 35 nmol per liter; normal, 65 to 148), a decline in the serum free thyroxine index, and a rise in the serum thyrotropin concentration (peak values, 7.2 to 166 mU per liter; normal, 0.5 to 5.5) 6 to 11 weeks after treatment. Two patients had elevated serum thyrotropin levels before treatment, which increased further after treatment. In two patients, these abnormal values returned to normal within 10 months. All five symptomatic patients had borderline or elevated serum antimicrosomal antibody titers after treatment; two had serum antibodies to thyroglobulin. Five of the seven patients with hypothyroidism (71 percent) but only 5 of the 27 euthyroid patients (19 percent) had evidence of tumor regression (P less than 0.02). None of 11 patients treated with interleukin-2 but not LAK cells had hypothyroidism. We conclude that treatment with interleukin-2 and LAK cells can cause hypothyroidism, possibly by exacerbating preexisting autoimmune thyroiditis, and that it may be associated with a favorable tumor response.
Source Information
Department of Medicine, New England Medical Center, Boston, MA 02111.
This article has been cited by other articles:
Kirkwood, J. M., Tarhini, A. A., Panelli, M. C., Moschos, S. J., Zarour, H. M., Butterfield, L. H., Gogas, H. J.
(2008). Next Generation of Immunotherapy for Melanoma. JCO
26: 3445-3455
[Abstract][Full Text]
Kaae, J., Wohlfahrt, J., Boyd, H. A., Wulf, H. C., Biggar, R. J., Melbye, M.
(2007). The Impact of Autoimmune Diseases on the Incidence and Prognosis of Cutaneous Malignant Melanoma. Cancer Epidemiol. Biomarkers Prev.
16: 1840-1844
[Abstract][Full Text]
McDermott, D. F., Atkins, M. B.
(2007). More Support for the Judicious Use of High-Dose Interleukin-2 in Patients With Advanced Melanoma. JCO
25: 3791-3793
[Full Text]
Tarhini, A. A., Kirkwood, J. M., Gooding, W. E., Cai, C., Agarwala, S. S.
(2007). Durable Complete Responses With High-Dose Bolus Interleukin-2 in Patients With Metastatic Melanoma Who Have Experienced Progression After Biochemotherapy. JCO
25: 3802-3807
[Abstract][Full Text]
Margolin, K., Atkins, M. B., Dutcher, J. P., Ernstoff, M. S., Smith, J. W. II, Clark, J. I., Baar, J., Sosman, J., Weber, J., Lathia, C., Brunetti, J., Cihon, F., Schwartz, B.
(2007). Phase I Trial of BAY 50-4798, an Interleukin-2-Specific Agonist in Advanced Melanoma and Renal Cancer. Clin. Cancer Res.
13: 3312-3319
[Abstract][Full Text]
Rini, B. I., Tamaskar, I., Shaheen, P., Salas, R., Garcia, J., Wood, L., Reddy, S., Dreicer, R., Bukowski, R. M.
(2007). Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. JNCI J Natl Cancer Inst
99: 81-83
[Abstract][Full Text]
Nelson, M., Hercbergs, A., Rybicki, L., Strome, M.
(2006). Association between development of hypothyroidism and improved survival in patients with head and neck cancer.. Arch Otolaryngol Head Neck Surg
132: 1041-1046
[Abstract][Full Text]
Ghori, F., Polder, K. D., Pinter-Brown, L. C., Hoff, A. O., Gagel, R. F., Sherman, S. I., Duvic, M.
(2006). Thyrotoxicosis after Denileukin Diftitox Therapy in Patients with Mycosis Fungoides. J. Clin. Endocrinol. Metab.
91: 2205-2208
[Abstract][Full Text]
Gogas, H., Ioannovich, J., Dafni, U., Stavropoulou-Giokas, C., Frangia, K., Tsoutsos, D., Panagiotou, P., Polyzos, A., Papadopoulos, O., Stratigos, A., Markopoulos, C., Bafaloukos, D., Pectasides, D., Fountzilas, G., Kirkwood, J. M.
(2006). Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon. NEJM
354: 709-718
[Abstract][Full Text]
Koon, H., Atkins, M.
(2006). Autoimmunity and Immunotherapy for Cancer. NEJM
354: 758-760
[Full Text]
Kirkwood, J. M.
(2005). Building Upon the Standard of Care in Adjuvant Therapy of High-Risk Melanoma. JCO
23: 8559-8563
[Full Text]
Ernstoff, M. S.
(2005). Self-Recognition and Tumor Response to Immunotherapy. JCO
23: 5875-5877
[Full Text]
Belin, R. M., Astor, B. C., Powe, N. R., Ladenson, P. W.
(2004). Smoke Exposure Is Associated with a Lower Prevalence of Serum Thyroid Autoantibodies and Thyrotropin Concentration Elevation and a Higher Prevalence of Mild Thyrotropin Concentration Suppression in the Third National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab.
89: 6077-6086
[Abstract][Full Text]
Pearce, E. N., Farwell, A. P., Braverman, L. E.
(2003). Thyroiditis. NEJM
348: 2646-2655
[Full Text]
Buzaid, A. C., Atkins, M.
(2001). Practical Guidelines for the Management of Biochemotherapy-related Toxicity in Melanoma. Clin. Cancer Res.
7: 2611-2619
[Abstract][Full Text]
De Paoli, P.
(2001). Immunological Effects of Interleukin-2 Therapy in Human Immunodeficiency Virus-Positive Subjects. CVI
8: 671-677
[Full Text]
Franzke, A., Peest, D., Probst-Kepper, M., Buer, J., Kirchner, G. I., Brabant, G., Kirchner, H., Ganser, A., Atzpodien, J.
(1999). Autoimmunity Resulting From Cytokine Treatment Predicts Long-Term Survival in Patients With Metastatic Renal Cell Cancer. JCO
17: 529-529
[Abstract][Full Text]
Yeung, S.-C. J., Chiu, A. C., Vassilopoulou-Sellin, R., Gagel, R. F.
(1998). The Endocrine Effects of Nonhormonal Antineoplastic Therapy. Endocr. Rev.
19: 144-172
[Abstract][Full Text]
Dayan, C. M., Daniels, G. H.
(1996). Chronic Autoimmune Thyroiditis. NEJM
335: 99-107
[Full Text]
Kausman, D., Isenberg, D.A.
(1994). Role of the Biologics in Autoimmunity. Lupus
3: 461-466
